Oncology

Scientists identify several new variants that affect the risk of lung cancer development.

Biosimilar to trastuzumab (Herceptin) observed to have no clinically significant differences than the reference product.

Trastuzumab is indicated as an adjuvant therapy for HER2-positive breast cancer, along with metastatic breast and gastric cancers.

Biomarker status could indicate palbociclib resistance in patients with estrogen receptor-positive breast cancer.

Promising immunotherapy may change the standard of care for kidney cancer.

Mice fed a tomato-rich diet experienced a 50% reduction in tumors.

Certain biomarkers influence outcomes in breast cancer patients treated with palbociclib.

Top articles of the week from The American Journal of Pharmacy Benefits.

A look at last week's top stories in the world of pharmacy.

CTL019 is a chimeric antigen receptor T cell therapy.

Top news of the day from across the health care landscape.

Abemaciclib is a CDK4/6 inhibitor being explored in advanced breast cancer.

Abemaciclib is a cyclin-dependent kinase 4 and 6 inhibitor for advanced breast cancer.

Dutasteride (Avodart) increases blood sugar, A1C, and blood lipids.

Two KEYNOTE trials were placed on full clinical hold and 1 partial clinical hold.

Scientists highlight the potential use of exosomes to detect and treat diseases.

Top articles of the week from Specialty Pharmacy Times.

Elevated protein levels may indicate a need for both chemotherapy and surgery for colon cancer.

Top news of the day from across the health care landscape.

Grape compounds may be an effective treatment option for colon cancer patients.

A specific immune T cell protects patients with lung cancer.

Sandoz has the highest number of biosimilars approved in Europe.

Some hair care products may cause increased cancer risk.

Top news of the day from across the health care landscape.

A new study looks into a potential link between hair care and breast cancer incidence.

Waiting to get treatment for breast cancer results is worse survival outcomes.

Conflicting breast cancer screening recommendations could result in late stage disease.

Radioactive particles attack skin and increase the risk of skin cancer.